Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIM-43004-1
- Development stage
- Preclinical
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous (used In Animal Models Via Infusion)
01
Overview
BIM-43004-1 is a **novel synthetic analog of peptide YY (PYY) (22-36)**, developed as a **selective agonist of the neuropeptide Y2 receptor**. It specifically binds to Y2 receptors found on human pancreatic cancer cells, resulting in a decrease in intracellular cyclic AMP (cAMP) levels and suppression of tumor growth in vivo[1]. As a Y2 receptor agonist, BIM-43004-1 was shown to decrease the growth of human pancreatic cancer xenografts in mice by 60.5% compared to control, and to reduce intracellular cAMP in these cells by over 50%. Its actions are distinct from native PYY but leverage similar biological pathways, impacting tumor biology as well as gastrointestinal functions[1][5].
02
Targets
NPY2R (Neuropeptide Y receptor subtype 2)
Beyond the preview
Go deeper on BIM-43004-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIM-43004-1.